Netherlands· NL-f8b54fd2c9cb

Ubretid 5 mg tabletten

A distigmine product containing distigminedibromide, registered in Netherlands by Euro Registratie Collectief B.V.. The same ATC class is registered in 7 of our 19 countries.

ATC N07AA03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about distigminedibromideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Distigmine is registered in 7 of 19 countries.

Countries holding a registration under ATC N07AA03 (distigmine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
3 of them publish a price we can compare per daily dose

Search distigmine products by name

Distigmine · ATC N07AA03

7 / 19 countries

Czechiaprice
Finlandprice
Germany
Japan
Netherlands
Polandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DISTIGMINEDIBROMIDE
Manufacturer: Euro Registratie Collectief B.V.
Country: Netherlands (NL)
ATC code: N07AA03
ATC class: Distigmine
Defined daily dose: 5 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
128191//07887

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Distigmine in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All distigmine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

Czechia · Ubretid
Germany · Ubretid
Poland · Ubretid
Slovakia · Ubretid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3a9563c1-e3e1-499f-ad9c-b827ce1de44f
GET /v1/drugs/3a9563c1-e3e1-499f-ad9c-b827ce1de44f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h07887_smpc.pdf",
  "strength": null,
  "atc_label": "Distigmine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg128191",
  "excipients": [
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "TALK (E 553b)",
    "ZETMEEL, GEPREGELATINEERD"
  ],
  "substances": [
    "DISTIGMINEDIBROMIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h128191.pdf",
  "authorised_at": "2021/06/24",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "128191//07887",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about distigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console